Home
- Destinations
- Vaccinations
- News & Announcements
- Travel Notices
- Diseases
- Yellow Book
- Find a Clinic
- Specific Groups & Settings
- Seasonal Flu & Travel
- Earthquake, Tsunami, and Radiation Release in Japan: Travel Information
- Traveling with Children
- Special Needs
- Disaster Relief
- Avian Flu & Travel
- Air & Cruise Ship Travel
- Air Travel Information For Travelers
- Cruise Ship Information for Travelers
- For Industry: Air
- CDC Measles Guidance for Commercial Aircraft Operators
- Interim Guidance for Protecting Travelers on Commercial Aircraft Serving Haiti During the Cholera Outbreak
- Reporting Onboard Deaths or Illnesses to CDC
- Onboard Death and Illness Response Tool for Cabin Crew
- Onboard Death and Illness Reporting Tool for Pilots
- CDC Guidance for Commercial Aircraft Operators: Seasonal Influenza
- Infection Control Guidelines for Cabin Crew Members on Commercial Aircraft
- For Industry: Cruise Ships
- Stay Healthy & Safe
- Illness & Injury Abroad
- Resources & Training
- Travel Podcasts
- RSS Feeds
Related Links
Chapter 3Infectious Diseases Related To Travel
Rabies
Charles E. Rupprecht, David R. Shlim
INFECTIOUS AGENT
Rabies is an acute, progressive, fatal encephalomyelitis caused by neurotropic viruses in the family Rhabdoviridae, genus Lyssavirus. Regardless of the viral variants found throughout the world, all lyssaviruses cause rabies, resulting in tens of millions of exposures and tens of thousands of human deaths each year.
MODE OF TRANSMISSION
Virus is present in the saliva of the biting rabid mammal. Transmission almost always occurs by an animal bite that inoculates virus into wounds. Virus inoculated into a wound does not enter the bloodstream but is taken up at a nerve synapse to travel to the brain, where it causes encephalitis. Virus may enter the nervous system fairly rapidly or may remain at the bite site for an extended period before gaining access to the nervous system. The approximate density of nerve endings in the region of the bite may increase the risk of developing encephalitis more rapidly. The hands and face, because of the relative density of nerve endings, are considered higher-risk exposures. Rarely, virus has been transmitted by exposures other than bites that introduce the agent into open wounds or mucous membranes.
All mammals are believed to be susceptible to infection, but major reservoirs are carnivores and bats. Although dogs are the main reservoir in developing countries, the epidemiology of the disease from one region or country to another differs enough to warrant the medical evaluation of all mammal bites. Bat bites anywhere in the world are a cause of concern and an indication for prophylaxis.
EPIDEMIOLOGY
Rabies is found on all continents, except Antarctica. Regionally, different viral variants are adapted to various mammalian hosts and perpetuate in dogs and wildlife, such as bats and some carnivores, including foxes, jackals, mongooses, raccoons, and skunks. In certain areas of the world, canine rabies remains highly enzootic, including but not limited to, parts of Africa, Asia, and Central and South America. Table 3-13 lists countries that have reported no cases of rabies during the most recent period for which information is available (formerly referred to as “rabies-free” countries).
Additional information about the global occurrence of rabies can be obtained from the following sources:
- World Health Organization (www.who.int/rabies/rabnet/en/)
- Rabies Bulletin—Europe (www.rbe.fli.bund.de)
- World Organization for Animal Health (www.oie.int/eng/en_index.htm)
- Local health authorities of the country, the embassy, or the local consulate’s office in the United States
These lists are provided only as a guide, because up-to-date information may not be available, surveillance standards vary, and reporting status can change suddenly as a result of disease reintroduction or emergence. The actual rate of possible rabies exposure in travelers has not been calculated with accuracy. However, studies have found a range of roughly 16–200 per 100,000 travelers based on differing criteria.
Table 3-13. Countries and political units that reported no indigenous cases of rabies during 20091
REGION | COUNTRIES |
---|---|
Africa | Cape Verde, Libya, Mauritius, Réunion, São Tomé and Príncipe, and Seychelles |
Americas | North: Bermuda, St. Pierre and Miquelon Caribbean: Antigua and Barbuda, Aruba, The Bahamas, Barbados, Cayman Islands, Dominica, Guadeloupe, Jamaica, Martinique, Montserrat, Netherlands Antilles, Saint Kitts (Saint Christopher) and Nevis, Saint Lucia, Saint Martin, Saint Vincent and Grenadines, Turks and Caicos, and Virgin Islands (UK and US) |
Asia and the Middle East | Hong Kong, Japan, Kuwait, Lebanon, Malaysia (Sabah), Qatar, Singapore, United Arab Emirates |
Europe | Austria, Belgium, Cyprus, Czech Republic,2 Denmark,2 Finland, Gibraltar, Greece, Iceland, Ireland, Isle of Man, Luxemburg, Netherlands,2 Norway, Portugal, Spain2 (except Ceuta and Melilla), Sweden, Switzerland, and United Kingdom2 |
Oceania3 | Australia,2 Cook Islands, Fiji, French Polynesia, Guam, Hawaii, Kiribati, Micronesia, New Caledonia, New Zealand, Northern Mariana Islands, Palau, Papua New Guinea, Samoa, and Vanuatu |
1Bat rabies may exist in some areas that are reportedly free of rabies in other mammals.
2Bat lyssaviruses are known to exist in these areas that are reportedly free of rabies in other mammals.
3Most of Pacific Oceania is reportedly "rabies-free."
CLINICAL PRESENTATION
Most patients will present after a documented, highly suspected, or likely exposure from a rabid animal. Clinical illness is compatible with acute, progressive encephalitis. After infection, the incubation period is highly variable, but it lasts approximately 1–3 months. The disease progresses acutely from a nonspecific, prodromal phase with fever and vague symptoms, to a neurologic phase, characterized by anxiety, paresis, paralysis, and other signs of encephalitis; spasms of swallowing muscles can be stimulated by the sight, sound, or perception of water (hydrophobia); and delirium and convulsions can develop, followed rapidly by coma and death.
Once clinical signs manifest, most patients die in 7–14 days.
DIAGNOSIS
Diagnosis is straightforward in an encephalitic patient recently exposed to a rabid animal. However, in lieu of a history of a documented exposure and the potential for long incubation periods of weeks to months after initial viral transmission, clinical diagnosis may be complicated by the variety of symptoms and the differential exclusion of other etiologic agents associated with encephalitis.
Definitive diagnosis can be made by demonstrating virus in neuronal tissue, corneal impressions, or nuchal biopsy, either by detecting viral antigens or amplicons. Additional detailed information on diagnostic testing may be obtained from CDC (www.cdc.gov/rabies). A specific serologic response to virus can also support the diagnosis in an encephalitic patient.
TREATMENT
No treatment is effective after the development of clinical signs, but the extremely rare case of recovery after extensive medical interventions offers hope that future experimental therapeutics may be developed.
PREVENTIVE MEASURES FOR TRAVELERS
Avoiding Animal Bites
Travelers to rabies-enzootic countries should be warned about the risk of acquiring rabies and educated in animal bite-prevention strategies. Travelers should avoid stray animals, be aware of their surroundings so that they do not accidentally surprise a stray dog, avoid contact with bats and other wildlife, and not carry or eat food while nonhuman primates are near. Casual exposure to cave air is not a concern, but visitors should be educated not to handle bats or other wildlife. Noncavers can occasionally encounter a bat, particularly during ecotourism events. Many bats have tiny teeth, and not all wounds may be apparent, compared with the lesions caused by carnivores. Any suspected or documented bite or scratch from a bat should be grounds for seeking postexposure prophylaxis.
Children are at higher risk for rabies exposures because of their smaller stature, which makes extensive bites more likely; their curiosity and attraction to animals; and the possibility that they may not report a possible exposure. Although licks to fresh wounds or mucus membranes are a theoretical risk of acquiring rabies and postexposure prophylaxis should be considered, there are no reported examples of rabies in travelers who were exposed in this manner.
Preexposure Vaccination
For certain international travelers, preexposure rabies vaccine may be recommended, based on the prevalence of rabies in the country to be visited, the availability of appropriate antirabies biologics, intended activities, and duration of stay. A decision to receive preexposure rabies immunization may also be based on the likelihood of repeat travel to at-risk destinations or taking up residence in a high-risk destination. Preexposure vaccination may be recommended for veterinarians, animal handlers, field biologists, cavers, missionaries, and certain laboratory workers. Table 3-14 provides criteria for preexposure vaccination. Serology for rabies virus neutralizing antibodies is used as one gauge for revaccination considerations. Lists of US laboratories performing rabies serology may be found on the CDC website (www.cdc.gov/rabies). Regardless of whether or not preexposure vaccine is administered, travelers going to areas with a high risk for rabies should be encouraged to purchase medical evacuation insurance (see Chapter 2, Travel Health Insurance and Evacuation Insurance).
In the United States, preexposure vaccination consists of a series of 3 injections with human diploid cell rabies vaccine (HDCV) or purified chick embryo cell (PCEC) vaccine. The schedule for this series is given in Table 3-15. Travelers should receive all 3 preexposure immunizations before travel. If 3 doses of rabies vaccine cannot be completed before travel, the traveler should not start the series, as it would be problematic to plan postexposure prophylaxis after a partial immunization series. Preexposure vaccination does not eliminate the need for additional medical attention after a rabies exposure, but it simplifies postexposure prophylaxis. Preexposure vaccination may also provide some degree of protection when there is an unapparent or unrecognized exposure to rabies virus and when postexposure prophylaxis might be delayed.
Travelers who have completed a 3-dose preexposure rabies immunization series or have received the full postexposure prophylaxis are considered preimmunized and do not require routine boosters, except after a likely rabies exposure. Periodic serum testing for rabies virus neutralizing antibody is not necessary in routine international travelers.
From 2007 through 2009, the supply of rabies vaccine in the United States was limited, and preexposure vaccination was not available to international travelers, except under special circumstances; supplies of vaccine were reserved for postexposure prophylaxis. This supply limitation has been resolved, and preexposure vaccination is now available to travelers.
Wound Management
Any animal bite or scratch should be thoroughly cleaned with copious amounts of soap and water and povidone iodine, if available. This local care will substantially reduce the risk for rabies. Wounds that might require suturing should have the suturing delayed for a few days. If suturing is necessary to control bleeding, or for functional or cosmetic reasons, rabies immune globulin (RIG), if indicated, should be administered into the wound before closing. The use of local anesthetic is not contraindicated in wound management.
Postexposure Prophylaxis
In Travelers Who Received Preexposure Vaccination
In the event of a possible rabies exposure in someone who received preexposure rabies vaccination, 2 boosters of an acceptable rabies vaccine are given on days 0 and 3 after the exposure. The booster doses should be modern cell culture vaccines, but they do not have to be the same brand as the vaccine given in the original preexposure immunization series.
In Travelers Who Did Not Receive Preexposure Vaccination
If preexposure rabies vaccination has not been given, postexposure prophylaxis consists of injections of RIG (20 IU/kg) and a series of 4 injections of rabies vaccine over 14 days (or 5 doses over a 1-month period in immunosuppressed patients). After wound cleansing, as much of the calculated amount of RIG (Table 3-16) as is anatomically feasible should be infiltrated around the wound. The dose injected around the wound may be as small as 0.5 mL if the wound is small or on a finger. If the wounds are extensive, the calculated dose of RIG must not be exceeded. If the calculated dose is inadequate to inject all the wounds, the RIG should be diluted with normal saline to extend the number of wounds that can be injected. This is a particular issue in children, whose body weight may be small in relation to the size and number of wounds.
The remainder of the RIG dose, if any, should be injected intramuscularly. Care should be taken to guarantee that this remaining amount of RIG is deposited in a muscle and not injected subcutaneously, which may decrease its effectiveness. The remaining RIG can be given in the deltoid muscle, on the opposite side of the initial vaccine dose. The anterior thigh is an alternative site.
RIG should not be given >7 days after the start of the postexposure vaccine series. This 7-day period does not relate to the time of the bite exposure itself. Postexposure prophylaxis, including RIG, should be initiated after a possible bite exposure even if there has been a considerable delay between the exposure and the traveler presenting for evaluation.
Human RIG is manufactured by plasmapheresis of blood from hyperimmunized volunteers. The manufactured quantity of human RIG falls short of worldwide requirements, and it is not available in many developing countries. Equine RIG or purified fractions of equine RIG have been used effectively in some developing countries where human RIG might not be available. If necessary, such heterologous products are preferable to no RIG.
The incidence of adverse reactions after the use of equine-derived RIG is low (0.8%–6.0%), and most reactions are minor. However, such products are not evaluated by US standards or regulated by the Food and Drug Administration, and their use cannot be unequivocally recommended. In addition, unpurified antirabies serum of equine origin might still be used in some countries where neither human nor equine RIG is available. The use of this antirabies serum is associated with higher rates of serious adverse reactions, including anaphylaxis.
Different postexposure vaccine schedules, alternative routes of administration, and other rabies vaccines besides HDCV and PCEC may be used abroad. Although not approved for sale in the United States, purified Vero cell rabies vaccine and purified chick embryo cell vaccine (manufactured abroad) are acceptable alternatives if available in a destination country. Assistance in managing complicated postexposure scenarios may be obtained from experienced travel medicine professionals, health departments, and CDC.
Rabies vaccine was once manufactured from viruses grown in animal brains, and some of these vaccines are still in use in developing countries. Typically, the brain-derived vaccines can be identified if the traveler is offered a large injection (5 mL) daily for 14–21 days. The traveler should not accept these vaccines, but rather travel to where acceptable vaccines and immune globulin are available.
Rabies Vaccine
Vaccine Safety and Adverse Reactions
Travelers should be advised that they may experience local reactions after vaccination, such as pain, erythema, swelling, or itching at the injection site, or mild systemic reactions, such as headache, nausea, abdominal pain, muscle aches, and dizziness. Approximately 6% of people receiving booster vaccinations with HDCV may experience an immune complex–like reaction characterized by urticaria, pruritus, and malaise. The likelihood of these reactions is less with PCEC. Once initiated, rabies postexposure prophylaxis should not be interrupted or discontinued because of local or mild systemic reactions to rabies vaccine.
Precautions and Contraindications
Pregnancy is not a contraindication to postexposure prophylaxis. In infants and children, the dose of HDCV or PCEC for preexposure or postexposure prophylaxis is the same as that recommended for adults. The dose of RIG for postexposure prophylaxis is based on body weight (Table 3-16).
Table 3-14. Criteria for preexposure immunization for rabies
RISK CATEGORY | NATURE OF RISK | TYPICAL POPULATIONS | PREEXPOSURE REGIMEN |
---|---|---|---|
Continuous |
Virus present continuously, often in high concentrations Specific exposures likely to go unrecognized Bite, nonbite, or aerosol exposure |
Rabies research laboratory workers,1 rabies biologics production workers | Primary course: serologic testing every 6 months; booster vaccination if antibody titer is below acceptable level2 |
Frequent |
Exposure usually episodic with source recognized, but exposure might also be unrecognized Bite, nonbite, or aerosol exposure possible |
Rabies diagnostic laboratory workers,1 cavers, veterinarians and staff, and animal control and wildlife workers in rabies-epizootic areas | Primary course: serologic testing every 2 years; booster vaccination if antibody titer is below acceptable level2 |
Infrequent (more than general population) |
Exposure nearly always episodic with source recognized Bite or nonbite exposure |
Veterinarians, animal control, and wildlife workers in areas with low rabies rates; veterinary students; and travelers visiting areas where rabies is enzootic and immediate access to appropriate medical care, including biologics, is limited | Primary course: no serologic testing or booster vaccination |
Rare (general population) | Exposure always episodic, with source recognized | US population at large, including individuals in rabies-epizootic areas | No preexposure immunization necessary |
1Judgment of relative risk and extra monitoring of vaccination status of laboratory workers is the responsibility of the laboratory supervisor (see www.cdc.gov/biosafety/publications/bmbl5 for more information).
2Preexposure booster immunization consists of 1 dose of human diploid cell (rabies) vaccine or purified chick embryo cell vaccine, 1.0-mL dose, intramuscular (deltoid area). Minimum acceptable antibody level is complete virus neutralization at a 1:5 serum dilution by the rapid fluorescent focus inhibition test. A booster dose should be administered if titer falls below this level.
Table 3-15. Preexposure immunization for rabies1
VACCINE | DOSE (mL) | NUMBER OF DOSES | SCHEDULE (DAYS) | ROUTE |
---|---|---|---|---|
HDCV | 1.0 | 3 | 0, 7, and 21 or 28 | Intramuscular |
PCEC | 1.0 | 3 | 0, 7, and 21 or 28 | Intramuscular |
Abbreviations: HDCV, human diploid cell vaccine; PCEC, purified chick embryo cell.
1Patients who are immunosuppressed by disease or medications should postpone preexposure vaccinations and consider avoiding activities for which rabies preexposure prophylaxis is indicated. When this course is not possible, immunosuppressed people who are at risk for rabies should have their antibody titers checked after vaccination.
Table 3-16. Postexposure immunization for rabies1
IMMUNIZA- TION STATUS |
VACCINE/ PRODUCT |
DOSE | NUMBER OF DOSES | SCHEDULE (DAYS) | ROUTE |
---|---|---|---|---|---|
Not previously immunized | RIG plus | 20 IU/kg body weight | 1 | 0 | Infiltrated at bite site (if possible); remainder intramuscular |
HDCV or PCEC | 1.0 mL | 42 | 0, 3, 7, 14 | Intramuscular | |
Previously immunized3,4 | HDCV or PCEC | 1.0 mL | 2 | 0, 3 | Intramuscular |
Abbreviations: RIG, rabies immune globulin; HDCV, human diploid cell vaccine; PCEC, purified chick embryo cell.
1All postexposure prophylaxis should begin with immediate, thorough cleansing of all wounds with soap and water.
2Five vaccine doses for the immunosuppressed patient.
3Preexposure immunization with HDCV or PCEC, prior postexposure prophylaxis with HDCV or PCEC, or people previously immunized with any other type of rabies vaccine and a documented history of positive rabies virus neutralizing antibody response to the prior vaccination.
4RIG should not be administered.
BIBLIOGRAPHY
- Gautret P, Adehossi E, Soula G, Soavi MJ, Delmont J, Rotivel Y, et al. Rabies exposure in international travelers: do we miss the target? Int J Infect Dis. 2010 Mar;14(3):e243–6.
- Rupprecht CE, Briggs D, Brown CM, Franka R, Katz SL, Kerr HD, et al. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices. MMWR Recomm Rep. 2010 Mar 19;59(RR-2):1–9.
- Rupprecht CE, Gibbons RV. Clinical practice. Prophylaxis against rabies. N Engl J Med. 2004 Dec 16;351(25):2626–35.
- Shaw MT, O’Brien B, Leggat PA. Rabies postexposure management of travelers presenting to travel health clinics in Auckland and Hamilton, New Zealand. J Travel Med. 2009 Jan–Feb;16(1):13–7.
- Smith A, Petrovic M, Solomon T, Fooks A. Death from rabies in a UK traveller returning from India. Euro Surveill. 2005 Jul;10(7):E050728 5.
- Strauss R, Granz A, Wassermann-Neuhold M, Krause R, Bago Z, Revilla-Fernandez S, et al. A human case of travel-related rabies in Austria, September 2004. Euro Surveill. 2005 Nov;10(11):225–6.
- van Thiel PP, de Bie RM, Eftimov F, Tepaske R, Zaaijer HL, van Doornum GJ, et al. Fatal human rabies due to Duvenhage virus from a bat in Kenya: failure of treatment with coma-induction, ketamine, and antiviral drugs. PLoS Negl Trop Dis. 2009;3(7):e428.
- Warrell MJ, Warrell DA. Rabies and other lyssavirus diseases. Lancet. 2004 Mar 20;363(9413):959–69.
- Yamamoto S, Iwasaki C, Oono H, Ninomiya K, Matsumura T. The first imported case of rabies into Japan in 36 years: a forgotten life-threatening disease. J Travel Med. 2008 Sep–Oct;15(5):372–4.
- WHO Expert Committee. WHO expert consultation on rabies. World Health Organ Tech Rep Ser. 2005;931:1–88.
Contact Us:
- Centers for Disease Control and Prevention
1600 Clifton Rd
Atlanta, GA 30333 - 800-CDC-INFO
(800-232-4636)
TTY: (888) 232-6348 - New Hours of Operation
8am-8pm ET/Monday-Friday
Closed Holidays - Contact CDC-INFO